Skip to content

Faculty profile

David Spaner

Back to faculty
ResearcherCancer and Cell BiologyUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.

Latest papers

  • BRCA1 deficiency induces NFκB-dependent type-I interferon signaling in fallopian tube epithelial cells.

    Neoplasia (New York, N.Y.) · 2026

  • ISGylation enhances dsRNA-induced interferon response and NFκB signaling in fallopian tube epithelial cells.

    The Journal of biological chemistry · 2024

  • A phase I study of romidepsin, gemcitabine, dexamethasone and cisplatin combination therapy in the treatment of peripheral T-cell and diffuse large B-cell lymphoma; the Canadian cancer trials group LY.15 study†.

    Leukemia & lymphoma · 2019

All 18 publications

Latest funding

  • Understanding the role of type 1 interferon in resistance to cancer immunotherapy

    CIHR · 2017 · Nominated PI

  • Targeting Interferon-beta in leukemia immunotherapy

    CIHR · 2016 · Nominated PI

    $459,000
  • Improving Glucocorticoid Therapy in Leukemia

    CIHR · 2013 · Nominated PI

    $377,124
All 5 grants and awards
Something wrong or missing on this profile? Suggest a correction